<DOC>
	<DOCNO>NCT01703637</DOCNO>
	<brief_summary>The purpose study explore difference efficacy safety sitagliptin , vildagliptin saxagliptin find one good treat type 2 diabetes mellitus .</brief_summary>
	<brief_title>Efficacy Safety Comparative Study Sitagliptin , Vildagliptin Saxagliptin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>sign informed consent diagnose T2DM woman childbearing potential require negative urine ; pregnancy test , agree use adequate contraception throughout ; study 4 week completion glycosylated hemoglobin range 6.59.5 % patient pregnancy lactation period ever receive kind oral Hypoglycemic drug recent 3 month patient currently receive treatment cytochrome P450 3A4 inducer depressor , systemic corticosteroid , human immunodeficiency virus antiviral medication gastrointestinal surgery could affect drug absorption patient haemoglobinopathy rapidly progress renal disease , autoimmune skin disorder recent history alcohol drug abuse within past 12 month contraindication list package insert study drug history acute chronic Pancreatitis currently type 1 diabetes ; history diabetic ketoacidosis hyperosmolar nonketonic coma New York Heart Association class III IV congestive heart failure ; leave ventricular ejection fraction ≤ 40 % ; major cardiovascular event within past 6 month significant abnormal liver function , define aspartate aminotransferase alanine aminotransferase &gt; 2 time upper limit normal total bilirubin &gt; 34 µmol/L ( &gt; 2 mg/dL ) ; history positive serologic evidence infectious liver disease clinical sign symptom active liver disease and/or significant abnormal liver function patient clinically significant abnormality identify physical examination , electrocardiogram ( ECG ) , laboratory test , judgment investigator , would compromise patient ' safety successful participation clinical study fast plasma glucose level &gt; 13.3mmol/l creatinine clearance rate ≤ 90ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Sitagliptin</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>Saxagliptin</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
</DOC>